CDK9 inhibition for the treatment of drug resistance in SCLC (A06+)

CDK9 抑制治疗 SCLC 耐药性 (A06)

• 批准号: 426730445
• 金额: --
• 依托单位: Labor für Tumorgenetik und Immunologie
• 依托单位国家: 德国
• 项目类别: Collaborative Research Centres
• 财政年份: 2019
• 资助国家: 德国
• 起止时间: 2018-12-31 至 2022-12-31
• 项目状态: 已结题
• 来源: https://gepris.dfg.de/gepris/projekt/426730445?language=en
• 关键词: CDK9; inhibition; treatment; drug; resistance

In the project N. Peltzer will investigate the therapeutic efficacy of inhibiting CDK9 as a strategy to break resistance to chemotherapy and to improve efficacy of immune checkpoint inhibition (ICI) in SCLC. She will also decipher the mechanisms of CDK9 inhibition (CDK9i)-mediated therapeutic effects. Since the therapeutic efficacy of CDK9i in NSCLC was previously shown to be due to inhibition of negative regulators of cell death, she will define whether the efficacy of CDK9i in SCLC, and occurrence of resistance to chemotherapy, depends on the expression of cell death components. Finally, having unraveled the mechanistic insights of Dinaciclib treatment, N. Peltzer will assess the therapeutic efficacy and synergism between Dinaciclib treatment with sensitization to immunogenic cell death with or without ICI.

在N. Peltzer将研究抑制CDK9的治疗效果，作为打破化疗耐药性和提高免疫检查点抑制（ICI）在SCLC中的疗效的策略。她还将破译CDK9抑制（CDK9i）介导的治疗作用的机制。由于CDK9i在NSCLC中的治疗功效先前显示是由于抑制细胞死亡的负调节因子，因此她将确定CDK9i在SCLC中的功效以及对化疗的耐药性的发生是否取决于细胞死亡组分的表达。最后，在揭示了Dinaciclib治疗的机制后，N. Peltzer将评估Dinaciclib治疗与免疫原性细胞死亡致敏（伴或不伴ICI）之间的疗效和协同作用。